| Business Summary | | Synsorb
Biotech
Inc.
is
a
pharmaceutical
company
dedicated
to
the
development
and
manufacturing
of
novel,
high-value
carbohydrate-based
therapies.
The
Company's
lead
product,
SYNSORB
Cd,
has
been
granted
"Fast
Track"
designation
by
the
US
FDA
and
is
undergoing
Phase
III
clinical
trials
at
centers
across
North
and
South
America.
SYNSORB
Cd
is
a
potential
treatment
for
recurrent
C.
difficile
Associated
Diarrhea
(CDAD),
a
condition
caused
by
antibiotic
use.
In
anticipation
of
future
commercialization,
Synsorb
has
built
a
cGMP-compliant
manufacturing
facility
that
has
the
capacity
to
meet
or
exceed
the
expected
global
demand
for
its
products.
A
pipeline
of
future
products
can
be
accessed
through
Synsorb's
carbohybrid
program.
The
Company
also
owns
6.75
million
shares
of
Oncolytics
Biotech
Inc.,
a
company
focused
on
the
development
of
Reolysin
(reovirus)
as
a
potential
cancer
therapeutic. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Synsorb
Biotech
Inc.
is
a
pharmaceutical
company
dedicated
to
the
development
and
manufacturing
of
novel,
high-value
carbohydrate-based
therapies.
For
the
three
months
ended
3/31/01,
revenues
decreased
38%
to
$225
thousand.
Net
loss
totaled
$4.1
million,
vs.
an
income
of
$137
thousand.
Revenues
reflect
lower
interest
income
and
the
absence
of
partnering
income.
Net
loss
also
reflects
the
recruitment
and
relocation
expenses
and
certain
staff
restructuring
charges. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
revenues
were
361;
after
tax
earnings
were
-3,687. (Preliminary; reported in thousands of dollars.) | More
from
Market Guide: Significant
Developments |
| Officers | |
| Position | Richard Casey | Chairman | David Cox, Ph.D. | Pres,
CEO | Bill Hogg | CFO,
VP-Fin. | John Frey | VP-
Clinical and Regulatory Affairs | Murray Ratcliffe, Ph.D. | VP-R&D
and Manufacturing |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|